II
Therapeutic Areas
PDS Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PDS0101 (Versamune®-HPV) | Recurrent/Metastatic HPV16+ Head & Neck Cancer | Phase 3 |
| PDS0101 + PDS01ADC + Chemotherapy | Recurrent/Metastatic HPV+ Head & Neck Cancer | Phase 2 |
| PDS0101 | Locally Advanced Cervical Cancer | Phase 2 |
| PDS0101 + other immunotherapies | Advanced HPV-Positive Cancers | Phase 2/1b |
| PDS0101 + PDS01ADC | Advanced Solid Tumors | Phase 1 |
| PDS0202 | Infectious Disease (Unspecified) | Preclinical |
Leadership Team at PDS Biotechnology
FB
Frank Bedu-Addo, Ph.D.
Chief Executive Officer, Director
ST
Stephan Toutain, M.S., M.B.A.
Chief Operating Officer
LB
Lars Boesgaard, M.B.A.
Chief Financial Officer
GC
Gregory Conn, Ph.D.
Chief Scientific Officer
GF
Gregory Freitag, J.D., CPA
Director
OW
Otis W. Brawley, M.D.
Director